{
    "nctId": "NCT05365230",
    "briefTitle": "A Randomized Trial Evaluating Personalized vs Guideline-based Well Follow-up Strategies for Patients With Early-stage Breast Cancer",
    "officialTitle": "A Randomized Trial Evaluating Personalized vs Guideline-based Well Follow-up Strategies for Patients With Early-stage Breast Cancer (REaCT-Wellness)",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "HEALTH_SERVICES_RESEARCH",
    "enrollmentCount": 264,
    "primaryOutcomeMeasure": "Health-Related Quality of Life",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Being referred to the Wellness Beyond Cancer Program (WBCP) for routine follow-up after completion of acute phase of treatment for invasive breast cancer\n\nExclusion Criteria:\n\n* History of prior invasive breast cancer, recurrent brest cancer or metastatic breast cancer\n* Currently receiving zoledronate, LHRH (Gonadotropin-releasing hormone) or abemaciclib",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}